Mylan Must Divest In EU For Upjohn Merger

European Commission Sets Out Requirements To Approve Deal

23 Apr 2020

The European Commission has approved Mylan’s merger with Pfizer’s Upjohn unit, on condition that the generics firm make a series of divestments in markets where the two firms’ strong positions and lack of other challengers would raise competition concerns.

Brexit — The European Commission has approved the merger, with conditions • Source: Shutterstock

Mylan can proceed with its plans to merge with Pfizer’s Upjohn unit, the European Commission has decided, provided that the generics firm make a series of divestments in 36 individual markets across Europe to address competition concerns that would result from the combination.

Having announced the merger – which will create a new combined company to be known as Viatris – in late...